Metabotropic glutamate receptors as targets for neuroprotective drugs (original) (raw)

Abstract

Anxiety disorders are highly prevalent psychiatric illnesses posing an important social and economic burden. Their current pharmacotherapy shows short term efficacy, though nearly one third of patients do not achieve sustained remission. There is, therefore, a strong medical need for new therapeutic agents acting through novel mechanisms of action. Considerable work has focused on metabotropic glutamate (mGlu) receptors as potential targets for novel anxiolytics. Ligands acting at mGlu receptors showed promising results in preclinical studies, whereas their efficacy was dubious in clinical trials. Recent preclinical and clinical studies have opened new prospects for targeting mGlu receptors to treat anxiety disorders. This review provides an outlook on these progresses.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (62)

  1. References and recommended reading Papers of particular interest, published within the period of review, have been highlighted as: of special interest of outstanding interest
  2. Kessler RC, Ruscio AM, Shear K, Wittchen HU: Epidemiology of anxiety disorders. Curr Top Behav Neurosci 2010, 2:21-35.
  3. Craske MG, Stein MB: Anxiety. Lancet 2016, 388:3048-3059.
  4. Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, Shea MT, Keller MB: Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005, 162:1179-1187.
  5. Stein MB, Sareen J: Generalized anxiety disorder. N Engl J Med 2015, 373:2059-2068.
  6. Tovote P, Fadok JP, Lu ¨thi A: Neuronal circuits for fear and anxiety. Nat Rev Neurosci 2015, 16:317-331.
  7. Griebel G, Holmes A: 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 2013, 12:667-687.
  8. Gillespie CF, Ressler KJ: Emotional learning and glutamate: translational perspectives. CNS Spectr 2005, 10:831-839.
  9. Myers KM, Carlezon WA Jr, Davis M: Glutamate receptors in extinction and extinction-based thepaies for psychiatric illness. Neuropsychopharmacology 2011, 36:274-293.
  10. Peterlik D, Flor PJ, Uschold-Schmidt N: The emerging role of metabotropic glutamate receptors in the pathophysiology of chronic stress-related disorders. Curr Neuropharmacol 2016, 14:514-539.
  11. Ferraguti F: Metabotropic glutamate receptors in amygdala functions. In mGlu Receptors. Edited by Ngomba RT, Di Giovanni G, Battaglia G, Nicoletti F. Springer; 2017:241-277.
  12. Steckler T, Lavreysen H, Oliveira AM, Aerts N, Van Craenendonck H, Prickaerts J, Megens A, Lesage AS: Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl) 2005, 179:198-206.
  13. Spooren W, Lesage A, Lavreysen H, Gasparini F, Steckler T: Metabotropic glutamate receptors: their therapeutic potential in anxiety. Curr Top Behav Neurosci 2010, 2:391-413.
  14. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD: Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005, 4:131-144.
  15. Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, Hodgson RA, Lu SX, Nicolussi E, Pond AJ et al.: The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl) 2005, 179:207-217.
  16. Brodkin J, Bradbury M, Busse C, Warren N, Bristow LJ, Varney MA: Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur J Neurosci 2002, 16:2241-2244.
  17. Nordquist RE, Durkin S, Jaeschke G, Spooren W: Stress-induced hyperthermia: effects of acute and repeated dosing of MPEP. Eur J Pharmacol 2007, 568:199-202.
  18. Porter RH, Jaeschke G, Spooren W, Ballard TM, Bu ¨ttelmann B, Kolczewski S, Peters JU, Prinssen E, Wichmann J, Vieira E et al.: Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005, 315:711-721.
  19. Jacob W, Gravius A, Pietraszek M, Nagel J, Belozertseva I, Shekunova E, Malyshkin A, Greco S, Barberi C, Danysz W: The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning. Neuropharmacology 2009, 57:97-108.
  20. Friedmann CTH, Davis LJ, Ciccone PE, Rubin RT: Phase II double blind controlled study of a new anxiolytic, fenobam (McN- 3377) vs placebo. Curr Ther Res 1980, 27:144-151.
  21. Park E, Sullivan JM, Planeta B, Gallezot JD, Lim K, Lin SF, Ropchan J, McCarthy TJ, Ding YS, Morris ED et al.: Test-retest reproducibility of the metabotropic glutamate receptor 5 ligand [18F]FPEB with bolus plus constant infusion in humans. Eur J Nucl Med Mol Imaging 2015, 42:1530-1541.
  22. Holmes SE, Girgenti MJ, Davis MT, Pietrzak RH, DellaGioia N, Nabulsi N, Matuskey D, Southwick S, Duman RS, Carson RE et al.: Altered metabotropic glutamate receptor markers in PTSD: in vivo and postmortem evidence. Proc Natl Acad Sci USA 2017, 114:8390-8395.
  23. This key study showed an increased cortical availability of mGlu5 recep- tors in post-traumatic stress disorder patients by PET imaging, using a radioligand that binds to the negative allosteric modulatory site of this receptor. This study also shows a positive correlation between mGlu5 receptor expression and avoidance symptoms.
  24. Akkus F, Terbeck S, Ametamey SM, Rufer MD, Treyer V, Burger C, Johayem A, Mancilla BG, Sovago J, Buck A, Hasler G: Metabotropic glutamate receptor 5 binding in patients with obsessive-compulsive disorder. Int J Neuropsychopharmacol 2014, 17:1915-1922.
  25. This interesting study reports a significant positive correlation between a clinical measure of obsessive-compulsive disorder symptom severity and mGlu5 receptor availability detected by PET imaging using the radiolabeled non-competitive antagonist ABP688.
  26. Wan Y, Feng G, Calakos N: Sapap3 deletion causes mGluR5- dependent silencing of AMPAR synapses. J Neurosci 2011, 31:1685-1691.
  27. Ade KK, Wan Y, Hamann HC, O'Hare JK, Guo W, Quian A, Kumar S, Bhagat S, Rodriguiz RM, Wetsel WC et al.: Increased metabotropic glutamate receptor 5 signaling underlies obsessive-compulsive disorder-like behavioral and striatal circuit abnormalities in mice. Biol Psychiatry 2016, 80:522-533.
  28. This key study demonstrates a causal role for increased mGlu5 receptor signaling at striatal circuits in mediating behavioral abnormalities with relevance to obsessive-compulsive disorder.
  29. Ferraguti F, Shigemoto R: Metabotropic glutamate receptors. Cell Tissue Res 2006, 326:483-504.
  30. Chaki S: mGlu2/3 receptor antagonists as novel antidepressants. Trends Pharmacol Sci 2017, 38:569-580.
  31. Linden AM, Baez M, Bergeron M, Schoepp DD: Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus. Neuropharmacology 2006, 51:213-228.
  32. Hetzenauer A, Corti C, Herdy S, Corsi M, Ferraguti F, Singewald N: Individual contribution of metabotropic glutamate receptor (mGlu) 2 and 3 to c-Fos expression pattern evoked by mGlu2/3 antagonism. Psychopharmacology (Berl) 2008, 201:1-13.
  33. Johnson PL, Fitz SD, Engleman EA, Svensson KA, Schkeryantz JM, Shekhar A: Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate- induced panic-like response in panic-vulnerable rats. J Psychopharmacol 2013, 27:152-161.
  34. Linden AM, Shannon H, Baez M, Yu JL, Koester A, Schoepp DD: Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Psychopharmacology (Berl) 2005, 179:284-291.
  35. Grillon C, Cordova J, Levine LR, Morgan CA 3rd: Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 2003, 168:446-454.
  36. Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ: LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003, 6:189-197.
  37. Kellner M, Muhtz C, Stark K, Yassouridis A, Arlt J, Wiedemann K: Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. Psychopharmacology (Berl) 2005, 179:310-315.
  38. Agorastos A, Demiralay C, Stiedl O, Muhtz C, Wiedermann K, Kellner M: Metabotropic glutamate 2/3 receptor agonism facilitates autonomic recovery after pharmacological panic challenge in healthy humans. Int Clin Psychopharmacol 2016, 31:176-178.
  39. Bergink V, Westenberg HG: Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int Clin Psychopharmacol 2005, 20:291-293.
  40. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD: Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008, 33:1603-1610.
  41. Raber J, Duvoisin RM: Novel metabotropic glutamate receptor 4 and glutamate receptor 8 therapeutics for the treatment of anxiety. Expert Opin Investig Drugs 2015, 24:519-528.
  42. Kalinichev M, Le Poul E, Bole ´a C, Girard F, Campo B, Fonsi M, Royer-Urios I, Browne SE, Uslaner JM, Davis MJ et al.: Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders. J Pharmacol Exp Ther 2014, 350:495-505.
  43. Sławi nska A, Wiero nska JM, Stachowicz K, Pałucha- Poniewiera A, Uberti MA, Bacolod MA, Doller D, Pilc A: Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu 4 receptor. Neuropharmacology 2013, 66:225-235.
  44. Davis MJ, Haley T, Duvoisin RM, Raber J: Measures of anxiety, sensorimotor function, and memory in male and female mGluR4À/À mice. Behav Brain Res 2012, 229:21-28.
  45. O' Connor RM, Pusceddu MM, Dinan TG, Cryan JF: Impact of early-life stress, on group III mGlu receptor levels in the rat hippocampus: effects of ketamine, electroconvulsive shock therapy and fluoxetine treatment. Neuropharmacology 2013, 66:236-241.
  46. Zussy C, Go ´mez-Santacana X, Rovira X, De Bundel D, Ferrazzo S, Bosch D, Asede D, Malhaire F, Acher F, Giraldo J et al.: Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4. Mol Psychiatry 2016 http:// dx.doi.org/10.1038/mp.2016.223. [Epub ahead of print].
  47. This paper reports how chronic pain-induced anxiety-like behavior can be abolished by an acute pharmacological activation of mGlu4 receptors either with the orthosteric agonist LSP4-2022 or the photoswitchable PAM optogluram. This study suggests that amygdala mGlu4 receptor signaling bypasses central sensitization processes to regulate the expression of affective and sensory symptoms of chronic pain.
  48. Goudet C, Vilar B, Courtiol T, Deltheil T, Bessiron T, Brabet I, Oueslati N, Rigault D, Bertrand HO, McLean H et al.: A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J 2012, 26:1682-1693.
  49. Mitsukawa K, Mombereau C, Lotscher E, Uzunov DP, van der Putten H, Flor PJ, Cryan JF: Metabotropic glutamate receptor subtype 7 ablation causes dysregulation of the HPA axis and increases hippocampal BDNF protein levels: implications for stress-related psychiatric disorders. Neuropsychopharmacology 2006, 31:1112-1122.
  50. O'Connor RM, Thakker DR, Schmutz M, van der Putten H, Hoyer D, Flor PJ, Cryan JF: Adult siRNA-induced knockdown of mGlu7 receptors reduces anxiety in the mouse. Neuropharmacology 2013, 72:66-73.
  51. Stachowicz K, Branski P, Klak K, van der Putten H, Cryan JF, Flor PJ, Andrzej P: Selective activation of metabotropic G- protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission. Behav Pharmacol 2008, 19:597-603.
  52. Sukoff-Rizzo SJ, Leonard SK, Gilbert A, Dollings P, Smith DL, Zhang MY, Di L, Platt BJ, Neal S, Dwyer JM et al.: The metabotropic glutamate receptor 7 allosteric modulator AMN082: a monoaminergic agent in disguise? J Pharmacol Exp Ther 2011, 338:345-352.
  53. Pelkey KA, Yuan X, Lavezzari G, Roche KW, McBain CJ: mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082. Neuropharmacology 2007, 52:108-117.
  54. Kalinichev M, Rouillier M, Girard F, Royer-Urios I, Bournique B, Finn T, Charvi D, Campo B, Le Poul E, Mutel V et al.: ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization. J Pharmacol Exp Ther 2013, 344:624-636.
  55. Gee CE, Peterlik D, Neuha ¨user C, Bouhelal R, Kaupmann K, Laue G, Uschold-Schmidt N, Feuerbach D, Zimmermann K, Ofner S et al.: Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior. J Biol Chem 2014, 289:10975-10987.
  56. Duvoisin RM, Pfankuch T, Wilson JM, Grabell J, Chhajlani V, Brown DG, Johnson E, Raber J: Acute pharmacological modulation of mGluR8 reduces measures of anxiety. Behav Brain Res 2010, 212:168-173.
  57. Duvoisin R, Villasana L, Davis M, Winder DG, Raber J: Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges. Behav Brain Res 2011, 221:50-54.
  58. Palazzo E, Fu Y, Ji G, Maione S, Neugebauer V: Group III mGluR7 and mGluR8 in the amygdala differentially modulate nocifensive and affective pain behaviors. Neuropharmacology 2008, 55:537-545.
  59. Stachowicz K, Kłak K, Pilc A, Chojnacka-Wo ´jcik E: Lack of the antianxiety-like effect of (S)-3,4-DCPG, an mGlu8 receptor agonist, after central administration in rats. Pharmacol Rep 2005, 57:856-860.
  60. Yin S, Noetzel MJ, Johnson KA, Zamorano R, Jalan-Sakrikar N, Gregory KJ, Conn PJ, Niswender CM: Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS. J Neurosci 2014, 34:79-94.
  61. This interesting article reports an interaction between mGlu4 and mGlu2 receptors compatible with the formation of heterodimers in native rodent tissue. This study also demonstrates altered efficacies of mGlu4 and mGlu2 receptor PAMs in cells co-expressing these receptors.
  62. Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM et al.: A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease. Mov Disord 2016, 31:1373-1380.